Endocan Measurement for Active Behçet Disease

ATEŞ, Orhan; Alkan Melikoglu, Meltem; KUL, Ayhan; ÖZTÜRK, Nurinnisa; ERKAYHAN, Gülsüm; KOÇER, İbrahim; UĞUR, Mahir

Endocan Measurement for Active Behçet Disease

Ayhan KUL, (Department of Physical Medicine and Rehabilitation, Medical Faculty of Atatürk University Erzurum, Turkey)

Orhan ATEŞ, (Department of Physical Medicine and Rehabilitation, Medical Faculty of Atatürk University Erzurum, Turkey)

Meltem ALKAN MELİKOĞLU, (Department of Physical Medicine and Rehabilitation, Medical Faculty of Atatürk University Erzurum, Turkey)

Mahir UĞUR, (Department of Physical Medicine and Rehabilitation, Medical Faculty of Atatürk University Erzurum, Turkey)

Nurinnisa ÖZTÜRK, (Department of Biochemistry, Medical Faculty of Atatürk University Erzurum, Turkey)

Gülsüm ERKAYHAN, (Department of Ophtalmologia, Mersin Public Hospital, Mersin, Turkey)

İbrahim KOÇER (Department of Ophtalmologia, Medical Faculty of Atatürk University Erzurum, Turkey)

Archives of Rheumatology

1 0

Yıl: 2017 Cilt: 32 Sayı: 3 Sayfa Aralığı: 197 - 202 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Endocan Measurement for Active Behçet Disease

Öz:

Objectives: This study aims to investigate the relationships between serum endocan, vascular endothelial growth factor (VEGF), and tumor necrosis factor-alpha (TNF-?) levels in active Behçet disease.Patients and methods: Forty patients with active Behçet disease (24 males, 16 females; mean age 37.6±8.7 years; range 20 to 50 years) and 40 healthy controls (22 males, 18 females; mean age 38.8±7.9 years; range 21 to 52 years) were included in this study. Both patient and control groups underwent a complete systemic and ophthalmic examination by the same specialist. Endocan, VEGF, and TNF-? levels were measured with an enzyme-linked immunosorbent assay kit in all subjects.Results: Serum endocan levels were 775.2±479.3 ng/mL and 275.8±145.8 ng/mL in the patient and control groups, respectively. VEGF levels were 1768.2±900.5 pg/mL and 980.2±135.3 pg/mL in the patient and control groups, respectively. TNF-? levels were 22.4±74.3 pg/mL-1 and 11.4±16.9 pg/mL-1 in the patient and control groups, respectively. There was a statistically significant difference between groups in terms of serum endocan, VEGF, and TNF-? levels. There was a significant positive correlation between serum endocan and VEGF levels in the patient group (r=0.630; p<0.001). Also, there was a significant positive correlation between serum endocan and TNF-? levels in the patient group (r=0.713; p<0.001).Conclusion: Serum endocan level may be a new marker in evaluation of both the prognosis and activity of Behçet disease.

Anahtar Kelime:

Konular: Romatoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Davatchi F, Sadeghi Abdollahi B, Chams-Davatchi C, Shahram F, Shams H, Nadji A, et al. The saga of diagnostic/classification criteria in Behcet's disease. Int J Rheum Dis 2015;18:594-605.
2. Çakar Özdal MP, Yazici A, Tüfek M, Öztürk F. Epidemiology of uveitis in a referral hospital in Turkey. Turk J Med Sci 2014;44:337-42.
3. Cartella S, Filippini M, Tincani A, Airo P. Prevalence of Behçet's disease in the province of Brescia in northern Italy. Clin Exp Rheumatol 2014;32:176.
4. Mat MC, Sevim A, Fresko I, Tüzün Y. Behçet's disease as a systemic disease. Clin Dermatol 2014;32:435-42. 5. Davatchi F. Behcet's disease. Int J Rheum Dis 2014;17:355-7.
6. Dogan D, Farah C. Behçet disease. Oftalmologia 2002;52:23-30. [Abstract]
7. Ozluk E, Balta I, Akoguz O, Kalkan G, Astarci M, Akbay G, et al. Histopathologic Study of Pathergy Test in Behçet's Disease. Indian J Dermatol 2014;59:630.
8. Bozkirli ED, Ke?kek SÖ, Kozano¤lu I, Yücel AE. High levels of endothelial progenitor cells can be associated with thrombosis in patients with Behçet's disease. Clin Exp Rheumatol 2014;32:49-53.
9. Onur E, Kabaroglu C, Inanir I, Var A, Guvenc Y, Gunay O, et al. Oxidative stress impairs endothelial nitric oxide levels in Behçets' disease. Cutan Ocul Toxicol 2011;30:217-20.
10. Acikgoz N, Ermi? N, Ya¤mur J, Cansel M, Karincao¤lu Y, Ata? H, et al. Elevated oxidative stress markers and its relationship with endothelial dysfunction in Behçet disease. Angiology 2011;62:296-300.
11. Seo K, Kitazawa T, Yoshino Y, Koga I, Ota Y. Characteristics of serum endocan levels in infection. PLoS One 2015;10:0123358.
12. Aparci M, Isilak Z, Uz O, Yalcin M, Kucuk U. Endocan and endothelial dysfunction. Angiology 2015;66:488- 9.
13. Balta S, Mikhailidis DP, Demirkol S, Celik T, Ozturk C, Iyisoy A. Endocan and atherosclerosis. Angiology 2015;66:490.
14. Wang XS, Yang W, Luo T, Wang JM, Jing YY. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers 2015;19:124-7.
15. Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R, et al. Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res 2013;73:1097-106.
16. Huang GW, Tao YM, Ding X. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci 2009;54:389-94.
17. Abid MR, Yi X, Yano K, Shih SC, Aird WC. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 2006;72:136-45.
18. Arida A, Sfikakis PP. Anti-cytokine biologic treatment beyond anti-TNF in Behçet's disease. Clin Exp Rheumatol 2014;32:149-55.
19. Mesquida M, Molins B, Llorenç V, Sainz de la Maza M, Hernandez MV, Espinosa G, et al. Proinflammatory cytokines and C-reactive protein in uveitis associated with Behçet's disease. Mediators Inflamm 2014;2014:396204.
20. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990;335:1078-80.
21. Gu X, Yu X, Dai H. Intravitreal injection of ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration. Curr Eye Res 2014;39:518-21.
22. Kose M, Emet S, Akpinar TS, Kocaaga M, Cakmak R, Akarsu M, et al. Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study. Angiology 2015;66:727-31.
23. Kapadia SR, Yakoob K, Nader S, Thomas JD, Mann DL, Griffin BP. Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 2000;36:208-12.
24. Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V. Behçet's syndrome: a critical digest of the 2013- 2014 literature. Clin Exp Rheumatol 2014;32:112-22.
25. Mat MC, Sevim A, Fresko I, Tüzün Y. Behçet's disease as a systemic disease.Clin Dermatol 2014;32:435-42.
26. Su YH, Shu KH, Hu CP, Cheng CH, Wu MJ, Yu TM, et al. Serum Endocan correlated with stage of chroni kidney disease and deterioration in renal transplant recipients. Transplant Proc 2014;46:323-7.
27. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006;1765:25-37.
28. Balta I, Balta S, Koryurek OM, Demirkol S, Mikhailidis DP, Celik T, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol 2014;70:291-6.
29. Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A, et al. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res 2007;313:1285-94.
30. Zhang SM, Zuo L, Zhou Q, Gui SY, Shi R, Wu Q, et al. Expression and distribution of endocan in human tissues. Biotech Histochem 2012;87:172-8.
31. Abu El-Asrar AM, Nawaz MI, De Hertogh G, Al-Kharashi AS, Van den Eynde K, Mohammad G, et al. The angiogenic biomarker endocan is upregulated in proliferative diabetic retinopathy and correlates with vascular endothelial growth factor. Curr Eye Res 2015;40:321-31.
32. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006;1765:25-37.
33. Voiosu T, Balanescu P, Bengu? A, Voiosu A, Baicu? CR, Barbu M, et al. Serum endocan levels are increased in patients with inflammatory bowel disease. Clin Lab 2014;60:505-10.
34. Lee W, Ku SK, Kim SW, Bae JS. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol 2014;229:620-30.
35. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006;1765:25-37.

APA	KUL A, ATEŞ O, Alkan Melikoglu M, UĞUR M, ÖZTÜRK N, ERKAYHAN G, KOÇER İ (2017). Endocan Measurement for Active Behçet Disease. , 197 - 202.
Chicago	KUL Ayhan,ATEŞ Orhan,Alkan Melikoglu Meltem,UĞUR Mahir,ÖZTÜRK Nurinnisa,ERKAYHAN Gülsüm,KOÇER İbrahim Endocan Measurement for Active Behçet Disease. (2017): 197 - 202.
MLA	KUL Ayhan,ATEŞ Orhan,Alkan Melikoglu Meltem,UĞUR Mahir,ÖZTÜRK Nurinnisa,ERKAYHAN Gülsüm,KOÇER İbrahim Endocan Measurement for Active Behçet Disease. , 2017, ss.197 - 202.
AMA	KUL A,ATEŞ O,Alkan Melikoglu M,UĞUR M,ÖZTÜRK N,ERKAYHAN G,KOÇER İ Endocan Measurement for Active Behçet Disease. . 2017; 197 - 202.
Vancouver	KUL A,ATEŞ O,Alkan Melikoglu M,UĞUR M,ÖZTÜRK N,ERKAYHAN G,KOÇER İ Endocan Measurement for Active Behçet Disease. . 2017; 197 - 202.
IEEE	KUL A,ATEŞ O,Alkan Melikoglu M,UĞUR M,ÖZTÜRK N,ERKAYHAN G,KOÇER İ "Endocan Measurement for Active Behçet Disease." , ss.197 - 202, 2017.
ISNAD	KUL, Ayhan vd. "Endocan Measurement for Active Behçet Disease". (2017), 197-202.

APA	KUL A, ATEŞ O, Alkan Melikoglu M, UĞUR M, ÖZTÜRK N, ERKAYHAN G, KOÇER İ (2017). Endocan Measurement for Active Behçet Disease. Archives of Rheumatology, 32(3), 197 - 202.
Chicago	KUL Ayhan,ATEŞ Orhan,Alkan Melikoglu Meltem,UĞUR Mahir,ÖZTÜRK Nurinnisa,ERKAYHAN Gülsüm,KOÇER İbrahim Endocan Measurement for Active Behçet Disease. Archives of Rheumatology 32, no.3 (2017): 197 - 202.
MLA	KUL Ayhan,ATEŞ Orhan,Alkan Melikoglu Meltem,UĞUR Mahir,ÖZTÜRK Nurinnisa,ERKAYHAN Gülsüm,KOÇER İbrahim Endocan Measurement for Active Behçet Disease. Archives of Rheumatology, vol.32, no.3, 2017, ss.197 - 202.
AMA	KUL A,ATEŞ O,Alkan Melikoglu M,UĞUR M,ÖZTÜRK N,ERKAYHAN G,KOÇER İ Endocan Measurement for Active Behçet Disease. Archives of Rheumatology. 2017; 32(3): 197 - 202.
Vancouver	KUL A,ATEŞ O,Alkan Melikoglu M,UĞUR M,ÖZTÜRK N,ERKAYHAN G,KOÇER İ Endocan Measurement for Active Behçet Disease. Archives of Rheumatology. 2017; 32(3): 197 - 202.
IEEE	KUL A,ATEŞ O,Alkan Melikoglu M,UĞUR M,ÖZTÜRK N,ERKAYHAN G,KOÇER İ "Endocan Measurement for Active Behçet Disease." Archives of Rheumatology, 32, ss.197 - 202, 2017.
ISNAD	KUL, Ayhan vd. "Endocan Measurement for Active Behçet Disease". Archives of Rheumatology 32/3 (2017), 197-202.